跳至主要内容
临床试验/NCT03728699
NCT03728699已完成不适用

Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy

Masonic Cancer Center, University of Minnesota1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2018年1月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
54
试验地点
1
主要终点
Abundance of Phyla

研究概览

简要总结

This is a prospective, observational study to collect stool and blood from acute myeloid leukemia patients undergoing intensive chemotherapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults (ages 18 - 99 years) undergoing inpatient intensive chemotherapy for newly diagnosed, refractory, or relapsed AML. Patients may or may not have been exposed to any type of therapy before.
  • Any intensive chemotherapy regimen defined as a planned ~4 week inpatient stay. Chemotherapy may be delivered for any number of days and on any schedule. Patients may be discharged from the hospital sooner than 4 weeks if the treating physician choose so, but the expectation at the initiation of chemotherapy must be ~4 weeks of inpatient stay, as is typical.
  • Able to provide written voluntary consent before performance of any study related procedure.

排除标准

  • 未提供

结局指标

主要结局

Abundance of Phyla

时间窗: Day 28

Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform

Abundance of Genera

时间窗: Day 28

Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform

次要结局

  • Microbiota Diversity (Stool)(Day 28)
  • Circulating Microbiota Diversity (Blood)(Day 28)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Microbiota Changes in Acute Myeloid Leukemia... | 临床试验